MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1 in SarcopeniaAge-Related Frailty

MYMDDelisted Stock  USD 1.82  0.02  1.09%   
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
MyMD Pharmaceuticals, Inc. , a clinical stage pharmaceutical company committed to developing novel therapies

Read at businesswire.com
businesswire News
  

MyMD Pharmaceuticals Fundamental Analysis

We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

MyMD Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

MyMD Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

MyMD Pharmaceuticals Related Equities

UBXUnity Biotechnology   4.17   
0%
91.0%
RXRXRecursion Pharmaceuticals   3.58   
0%
78.0%
GOVXGeoVax Labs   2.26   
0%
49.0%
DSGNDesign Therapeutics   2.25   
0%
49.0%
BOLTBolt Biotherapeutics   2.00   
0%
43.0%
KZRKezar Life   1.86   
0%
40.0%
NVCTNuvectis Pharma   1.53   
0%
33.0%
XBIOXenetic Biosciences   1.47   
0%
32.0%
REPLReplimune   1.30   
0%
28.0%
LYRALyra Therapeutics   1.18   
0%
25.0%
AVIRAtea Pharmaceuticals   0.31   
0%
6.0%
PASGPassage Bio   0.15   
0%
3.0%
SRZNSurrozen   0.08   
0%
1.0%
NBYNovaBay Pharmaceuticals     
0%
1.0%
LGNDLigand Pharmaceuticals   0.37   
8.0%
0%
KRONKronos Bio   1.04   
22.0%
0%
LYELLyell Immunopharma   1.61   
35.0%
0%
ORICOric Pharmaceuticals   1.68   
36.0%
0%
GOSSGossamer Bio   2.33   
51.0%
0%
KROSKeros Therapeutics   2.39   
52.0%
0%
REVBRevelation Biosciences   3.23   
70.0%
0%
LRMRLarimar Therapeutics   4.55   
100.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Consideration for investing in MyMD Stock

If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stocks Directory
Find actively traded stocks across global markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated